Skip to Content
chevron-left chevron-right chevron-up chevron-right chevron-left arrow-back star phone quote checkbox-checked search wrench info shield play connection mobile coin-dollar spoon-knife ticket pushpin location gift fire feed bubbles home heart calendar price-tag credit-card clock envelop facebook instagram twitter youtube pinterest yelp google reddit linkedin envelope bbb pinterest homeadvisor angies

USOR #19062

A Phase 1B/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of Tazemetostat or placebo in combination with Lenalidomide plus Rituximab in subjects with relapsed/refractory follicular lymphoma. (EZH-302)